Xtandi 40 MG tablet 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FCFQ7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $59,209
Award facts
- Contract value 100% obligated
- $59,208.62 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $59,208.62 to DMS Pharmaceutical Group Inc. for 120 tablets of Xtandi 40 mg on January 27, 2026, with completion targeted for January 28, 2026. This firm fixed-price delivery order was issued without a set-aside designation, enabling the woman-owned small business pharmaceutical wholesaler to compete in unrestricted federal procurement. DMS Pharmaceutical Group, headquartered in Park Ridge, Illinois, is the awardee, and the place of performance is located in Park Ridge. The delivery order was funded by the Defense Logistics Agency and represents a routine pharmaceutical supply transaction for federal military healthcare operations.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which carries a $499.9 billion ceiling and runs through December 31, 2036. The PPV-G GEN V represents a $30.3 billion federal acquisition strategy designed to establish regional prime vendor contractors supplying comprehensive pharmaceutical products—including branded and generic prescription drugs, biologics, vaccines, and medical consumables—to military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance across numerous delivery orders demonstrates its capability as a critical supplier within the Department of Defense's pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FCFQ7?
SPE2DR26FCFQ7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26FCFQ7 worth?
The government has obligated $59,209 on SPE2DR26FCFQ7.
Is contract SPE2DR26FCFQ7 an order under another contract?
Yes. SPE2DR26FCFQ7 is a delivery order under SPE2DR25D9133, an indefinite delivery contract.
Was contract SPE2DR26FCFQ7 competed?
The extent of competition for SPE2DR26FCFQ7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award